OBJECTIVE: To examine the lifetime prevalence of mood and anxiety disorders in patients with systemic lupus erythematosus (SLE). Demographic and disease-related variables were examined for association with lifetime major depressive disorder (MDD) and the presence of any mood or anxiety disorder. METHODS: Three hundred twenty-six white women with SLE completed the Composite International Diagnostic Interview and the Systemic Lupus Activity Questionnaire, a self-report measure of SLE disease activity. The binomial test was used to compare the prevalence of psychiatric diagnoses in patients with SLE with a population sample of white women. RESULTS: Sixty-five percent of the participants received a lifetime mood or anxiety diagnosis. MDD (47%), specific phobia (24%), panic disorder (16%), obsessive-compulsive disorder (9%), and bipolar I disorder (6%) were more common among patients with SLE than among other white women (P = 0.00009 for specific phobia; for all other values P = 0.00001). Although most patients with histories of mood disorders reported their psychiatric symptoms to a medical provider, a substantial number of patients with anxiety disorders did not. Self-reported disease activity was associated with a lifetime history of MDD (P = 0.001) and presence of a mood or anxiety disorder (P = 0.001), after controlling for demographic and clinical characteristics. CONCLUSION: Several mood and anxiety disorders were more common in women with SLE compared with the general population, and disease activity may contribute to this higher risk. Brief self-report questionnaires may help providers identify patients with these conditions, particularly when patients are reluctant to disclose their symptoms.
OBJECTIVE: To examine the lifetime prevalence of mood and anxiety disorders in patients with systemic lupus erythematosus (SLE). Demographic and disease-related variables were examined for association with lifetime major depressive disorder (MDD) and the presence of any mood or anxiety disorder. METHODS: Three hundred twenty-six white women with SLE completed the Composite International Diagnostic Interview and the Systemic Lupus Activity Questionnaire, a self-report measure of SLE disease activity. The binomial test was used to compare the prevalence of psychiatric diagnoses in patients with SLE with a population sample of white women. RESULTS: Sixty-five percent of the participants received a lifetime mood or anxiety diagnosis. MDD (47%), specific phobia (24%), panic disorder (16%), obsessive-compulsive disorder (9%), and bipolar I disorder (6%) were more common among patients with SLE than among other white women (P = 0.00009 for specific phobia; for all other values P = 0.00001). Although most patients with histories of mood disorders reported their psychiatric symptoms to a medical provider, a substantial number of patients with anxiety disorders did not. Self-reported disease activity was associated with a lifetime history of MDD (P = 0.001) and presence of a mood or anxiety disorder (P = 0.001), after controlling for demographic and clinical characteristics. CONCLUSION: Several mood and anxiety disorders were more common in women with SLE compared with the general population, and disease activity may contribute to this higher risk. Brief self-report questionnaires may help providers identify patients with these conditions, particularly when patients are reluctant to disclose their symptoms.
Authors: E P Zorrilla; L Luborsky; J R McKay; R Rosenthal; A Houldin; A Tax; R McCorkle; D A Seligman; K Schmidt Journal: Brain Behav Immun Date: 2001-09 Impact factor: 7.217
Authors: H M Bastian; J M Roseman; G McGwin; G S Alarcón; A W Friedman; B J Fessler; B A Baethge; J D Reveille Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: R Ishikura; N Morimoto; K Tanaka; N Kinukawa; S Yoshizawa; T Horiuchi; H Nakashima; T Otsuka Journal: Clin Rheumatol Date: 2001 Impact factor: 2.980
Authors: J Seguí; M Ramos-Casals; M García-Carrasco; T de Flores; R Cervera; M Valdés; J Font; M Ingelmo Journal: Lupus Date: 2000 Impact factor: 2.911
Authors: E W Karlson; L H Daltroy; C Rivest; R Ramsey-Goldman; E A Wright; A J Partridge; M H Liang; P R Fortin Journal: Lupus Date: 2003 Impact factor: 2.911
Authors: Fabiano G Nery; Eduardo F Borba; Vilma S T Viana; John P Hatch; Jair C Soares; Eloísa Bonfá; Francisco Lotufo Neto Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2007-11-19 Impact factor: 5.067
Authors: Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang Journal: JAMA Date: 2003-06-18 Impact factor: 56.272
Authors: Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Carol M Greco; Tracy Li; Abdus Sattar; Amy H Kao; Natalya Danchenko; Daniel Edmundowicz; Kim Sutton-Tyrrell; Russell P Tracy; Lewis H Kuller; Susan Manzi Journal: J Rheumatol Date: 2011-12-15 Impact factor: 4.666
Authors: Sophia Attwells; Elaine Setiawan; Alan A Wilson; Pablo M Rusjan; Romina Mizrahi; Laura Miler; Cynthia Xu; Margaret Anne Richter; Alan Kahn; Stephen J Kish; Sylvain Houle; Lakshmi Ravindran; Jeffrey H Meyer Journal: JAMA Psychiatry Date: 2017-08-01 Impact factor: 21.596
Authors: Thomas Hyphantis; Konstantinos Kotsis; Niki Tsifetaki; Francis Creed; Alexandros A Drosos; André F Carvalho; Paraskevi V Voulgari Journal: Clin Rheumatol Date: 2013-01-18 Impact factor: 2.980